Today there is a renewed commitment to eliminating malaria and a sense of urgency spurred by the specter of drug resistance.
Cambodia was ground zero in the early 1960s for the first wave of drug-resistant malaria, which rendered the drug of choice, chloroquine, ineffective against the most lethal of the four strains of the parasite. This resistance was a consequence of multiple factors, including ineffective and counterfeit drugs, and poor patient adherence to the prescribed treatment.
This drug resistance brought a kind of emergency.
With the single-drug regimen sidelined, scientists sought new compounds and combinations that could clear the parasite from a patient’s bloodstream. Today, artemisinin is the key ingredient in the most effective of these; when paired with another drug, ACT – or artemisinin combination therapy – is the gold standard for malaria treatment.
But of five ACT regimens approved by the World Health Organization, four have been rendered useless by drug resistance in Cambodia. Drug resistance has also been found in the other countries of the region; if the resistance seen in the Mekong were to spread to India or sub-Saharan Africa – where the malaria burden is highest – it would be a devastating setback to global elimination efforts and almost certainly reverse the hard-won decline in death rates.
“This drug resistance brought a kind of emergency,” said Naeem Durrani, program coordinator for UNOPS, which manages the Global Fund’s Regional Artemisinin-resistance Initiative (RAI) grant in Cambodia. “The goal here, and the only answer, is elimination. RAI is helping to intensify efforts to eliminate multidrug-resistant malaria within its geographical borders and prevent its spread to other regions, other countries.”
And it’s working.